nodes	percent_of_prediction	percent_of_DWPC	metapath
Albendazole—ABCB1—Lisinopril—dilated cardiomyopathy	0.249	0.532	CbGbCtD
Albendazole—ABCB1—Spironolactone—dilated cardiomyopathy	0.219	0.468	CbGbCtD
Albendazole—TUBA1A—Pathogenic Escherichia coli infection—TUBB—dilated cardiomyopathy	0.0138	0.0507	CbGpPWpGaD
Albendazole—TUBA1A—Loss of Nlp from mitotic centrosomes—TUBB—dilated cardiomyopathy	0.0127	0.0467	CbGpPWpGaD
Albendazole—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.0118	0.0526	CcSEcCtD
Albendazole—TUBA1A—Parkin-Ubiquitin Proteasomal System pathway—TUBB—dilated cardiomyopathy	0.0114	0.0418	CbGpPWpGaD
Albendazole—TUBA1A—Centrosome maturation—TUBB—dilated cardiomyopathy	0.0113	0.0413	CbGpPWpGaD
Albendazole—TUBA1A—Loss of Nlp from mitotic centrosomes—ALMS1—dilated cardiomyopathy	0.0107	0.0391	CbGpPWpGaD
Albendazole—TUBA1A—Regulation of PLK1 Activity at G2/M Transition—TUBB—dilated cardiomyopathy	0.0104	0.038	CbGpPWpGaD
Albendazole—TUBA1A—Centrosome maturation—ALMS1—dilated cardiomyopathy	0.00946	0.0346	CbGpPWpGaD
Albendazole—TUBA1A—Regulation of PLK1 Activity at G2/M Transition—ALMS1—dilated cardiomyopathy	0.00869	0.0318	CbGpPWpGaD
Albendazole—TUBB4B—Pathogenic Escherichia coli infection—TUBB—dilated cardiomyopathy	0.00836	0.0306	CbGpPWpGaD
Albendazole—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00832	0.0371	CcSEcCtD
Albendazole—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00783	0.0349	CcSEcCtD
Albendazole—TUBA1A—G2/M Transition—TUBB—dilated cardiomyopathy	0.00779	0.0285	CbGpPWpGaD
Albendazole—TUBB4B—Loss of Nlp from mitotic centrosomes—TUBB—dilated cardiomyopathy	0.0077	0.0282	CbGpPWpGaD
Albendazole—TUBA1A—Mitotic G2-G2/M phases—TUBB—dilated cardiomyopathy	0.00768	0.0281	CbGpPWpGaD
Albendazole—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00767	0.0342	CcSEcCtD
Albendazole—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00713	0.0318	CcSEcCtD
Albendazole—TUBB4B—Parkin-Ubiquitin Proteasomal System pathway—TUBB—dilated cardiomyopathy	0.0069	0.0252	CbGpPWpGaD
Albendazole—TUBB4B—Centrosome maturation—TUBB—dilated cardiomyopathy	0.00682	0.025	CbGpPWpGaD
Albendazole—Alopecia—Spironolactone—dilated cardiomyopathy	0.00666	0.0297	CcSEcCtD
Albendazole—TUBA1A—G2/M Transition—ALMS1—dilated cardiomyopathy	0.00652	0.0239	CbGpPWpGaD
Albendazole—TUBB4B—Loss of Nlp from mitotic centrosomes—ALMS1—dilated cardiomyopathy	0.00645	0.0236	CbGpPWpGaD
Albendazole—TUBA1A—Mitotic G2-G2/M phases—ALMS1—dilated cardiomyopathy	0.00643	0.0236	CbGpPWpGaD
Albendazole—TUBB4B—Regulation of PLK1 Activity at G2/M Transition—TUBB—dilated cardiomyopathy	0.00626	0.0229	CbGpPWpGaD
Albendazole—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00587	0.0262	CcSEcCtD
Albendazole—TUBB4B—Centrosome maturation—ALMS1—dilated cardiomyopathy	0.00571	0.0209	CbGpPWpGaD
Albendazole—TUBA1A—cardiac ventricle—dilated cardiomyopathy	0.00555	0.161	CbGeAlD
Albendazole—TUBB4B—Regulation of PLK1 Activity at G2/M Transition—ALMS1—dilated cardiomyopathy	0.00525	0.0192	CbGpPWpGaD
Albendazole—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00524	0.0234	CcSEcCtD
Albendazole—TUBA1A—myocardium—dilated cardiomyopathy	0.00522	0.151	CbGeAlD
Albendazole—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00482	0.0215	CcSEcCtD
Albendazole—TUBB4B—G2/M Transition—TUBB—dilated cardiomyopathy	0.0047	0.0172	CbGpPWpGaD
Albendazole—TUBB4B—Mitotic G2-G2/M phases—TUBB—dilated cardiomyopathy	0.00464	0.017	CbGpPWpGaD
Albendazole—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00453	0.0202	CcSEcCtD
Albendazole—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00432	0.0193	CcSEcCtD
Albendazole—TUBA1A—Pathogenic Escherichia coli infection—ITGB1—dilated cardiomyopathy	0.0043	0.0157	CbGpPWpGaD
Albendazole—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00426	0.019	CcSEcCtD
Albendazole—Urticaria—Spironolactone—dilated cardiomyopathy	0.00425	0.019	CcSEcCtD
Albendazole—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00423	0.0189	CcSEcCtD
Albendazole—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00405	0.0181	CcSEcCtD
Albendazole—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00402	0.0179	CcSEcCtD
Albendazole—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00395	0.0176	CcSEcCtD
Albendazole—TUBB4B—G2/M Transition—ALMS1—dilated cardiomyopathy	0.00394	0.0144	CbGpPWpGaD
Albendazole—TUBB4B—Mitotic G2-G2/M phases—ALMS1—dilated cardiomyopathy	0.00388	0.0142	CbGpPWpGaD
Albendazole—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00388	0.0173	CcSEcCtD
Albendazole—Immune system disorder—Furosemide—dilated cardiomyopathy	0.0037	0.0165	CcSEcCtD
Albendazole—TUBB4B—cardiac ventricle—dilated cardiomyopathy	0.0037	0.107	CbGeAlD
Albendazole—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00365	0.0163	CcSEcCtD
Albendazole—TUBA1A—heart—dilated cardiomyopathy	0.00364	0.106	CbGeAlD
Albendazole—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00359	0.016	CcSEcCtD
Albendazole—Dizziness—Spironolactone—dilated cardiomyopathy	0.00354	0.0158	CcSEcCtD
Albendazole—TUBB4B—myocardium—dilated cardiomyopathy	0.00348	0.101	CbGeAlD
Albendazole—Vomiting—Spironolactone—dilated cardiomyopathy	0.0034	0.0152	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.0034	0.0151	CcSEcCtD
Albendazole—Rash—Spironolactone—dilated cardiomyopathy	0.00338	0.015	CcSEcCtD
Albendazole—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00337	0.015	CcSEcCtD
Albendazole—Headache—Spironolactone—dilated cardiomyopathy	0.00335	0.015	CcSEcCtD
Albendazole—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00324	0.0144	CcSEcCtD
Albendazole—Vertigo—Furosemide—dilated cardiomyopathy	0.00321	0.0143	CcSEcCtD
Albendazole—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.0032	0.0143	CcSEcCtD
Albendazole—Leukopenia—Furosemide—dilated cardiomyopathy	0.0032	0.0142	CcSEcCtD
Albendazole—Nausea—Spironolactone—dilated cardiomyopathy	0.00318	0.0142	CcSEcCtD
Albendazole—TUBA1A—cardiac atrium—dilated cardiomyopathy	0.00312	0.0903	CbGeAlD
Albendazole—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00308	0.0137	CcSEcCtD
Albendazole—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00304	0.0135	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00302	0.0135	CcSEcCtD
Albendazole—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00302	0.0134	CcSEcCtD
Albendazole—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00291	0.013	CcSEcCtD
Albendazole—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00285	0.0127	CcSEcCtD
Albendazole—Skin disorder—Furosemide—dilated cardiomyopathy	0.00283	0.0126	CcSEcCtD
Albendazole—Alopecia—Lisinopril—dilated cardiomyopathy	0.00272	0.0121	CcSEcCtD
Albendazole—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.0027	0.0099	CbGpPWpGaD
Albendazole—TUBA1A—p73 transcription factor network—FAS—dilated cardiomyopathy	0.00264	0.00965	CbGpPWpGaD
Albendazole—TUBB4B—Pathogenic Escherichia coli infection—ITGB1—dilated cardiomyopathy	0.00259	0.0095	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00248	0.00907	CbGpPWpGaD
Albendazole—TUBB4B—heart—dilated cardiomyopathy	0.00243	0.0704	CbGeAlD
Albendazole—Vertigo—Lisinopril—dilated cardiomyopathy	0.00241	0.0107	CcSEcCtD
Albendazole—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0024	0.0107	CcSEcCtD
Albendazole—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00238	0.0106	CcSEcCtD
Albendazole—Urticaria—Furosemide—dilated cardiomyopathy	0.00231	0.0103	CcSEcCtD
Albendazole—Abdominal pain—Furosemide—dilated cardiomyopathy	0.0023	0.0103	CcSEcCtD
Albendazole—Body temperature increased—Furosemide—dilated cardiomyopathy	0.0023	0.0103	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00226	0.0101	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—TUBB—dilated cardiomyopathy	0.00221	0.00811	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00221	0.00808	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00215	0.00787	CbGpPWpGaD
Albendazole—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00215	0.00957	CcSEcCtD
Albendazole—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00214	0.00954	CcSEcCtD
Albendazole—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00212	0.00946	CcSEcCtD
Albendazole—CYP1A1—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.0021	0.0077	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.0021	0.0077	CbGpPWpGaD
Albendazole—TUBB4B—cardiac atrium—dilated cardiomyopathy	0.00208	0.0602	CbGeAlD
Albendazole—TUBA1A—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00208	0.0076	CbGpPWpGaD
Albendazole—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00207	0.06	CbGeAlD
Albendazole—TUBA1A—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.00204	0.00747	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.00204	0.00747	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—EMD—dilated cardiomyopathy	0.00197	0.00723	CbGpPWpGaD
Albendazole—Dizziness—Furosemide—dilated cardiomyopathy	0.00193	0.00859	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00186	0.00679	CbGpPWpGaD
Albendazole—Vomiting—Furosemide—dilated cardiomyopathy	0.00185	0.00826	CcSEcCtD
Albendazole—Rash—Furosemide—dilated cardiomyopathy	0.00184	0.00819	CcSEcCtD
Albendazole—Dermatitis—Furosemide—dilated cardiomyopathy	0.00184	0.00818	CcSEcCtD
Albendazole—Headache—Furosemide—dilated cardiomyopathy	0.00183	0.00814	CcSEcCtD
Albendazole—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00179	0.00797	CcSEcCtD
Albendazole—Urticaria—Lisinopril—dilated cardiomyopathy	0.00174	0.00774	CcSEcCtD
Albendazole—Nausea—Furosemide—dilated cardiomyopathy	0.00173	0.00771	CcSEcCtD
Albendazole—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00173	0.0077	CcSEcCtD
Albendazole—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00173	0.0077	CcSEcCtD
Albendazole—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00161	0.00718	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.0015	0.00547	CbGpPWpGaD
Albendazole—CYP1A1—Oxidative Stress—SOD2—dilated cardiomyopathy	0.00147	0.00539	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00145	0.00531	CbGpPWpGaD
Albendazole—Dizziness—Lisinopril—dilated cardiomyopathy	0.00145	0.00644	CcSEcCtD
Albendazole—CYP1A1—Oxidative Stress—GPX1—dilated cardiomyopathy	0.0014	0.00514	CbGpPWpGaD
Albendazole—Vomiting—Lisinopril—dilated cardiomyopathy	0.00139	0.0062	CcSEcCtD
Albendazole—Rash—Lisinopril—dilated cardiomyopathy	0.00138	0.00614	CcSEcCtD
Albendazole—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00138	0.00614	CcSEcCtD
Albendazole—Headache—Lisinopril—dilated cardiomyopathy	0.00137	0.0061	CcSEcCtD
Albendazole—CYP1A1—heart—dilated cardiomyopathy	0.00136	0.0394	CbGeAlD
Albendazole—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00134	0.00491	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TUBB—dilated cardiomyopathy	0.00134	0.0049	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00133	0.00488	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.00131	0.00481	CbGpPWpGaD
Albendazole—Nausea—Lisinopril—dilated cardiomyopathy	0.0013	0.00579	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00125	0.00459	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.00123	0.00451	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.00123	0.00451	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—EMD—dilated cardiomyopathy	0.00119	0.00436	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TMPO—dilated cardiomyopathy	0.00117	0.0043	CbGpPWpGaD
Albendazole—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.00116	0.0337	CbGeAlD
Albendazole—TUBB4B—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00112	0.0041	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.00108	0.00395	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00103	0.00376	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.001	0.00366	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.001	0.00366	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000971	0.00356	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—LMNA—dilated cardiomyopathy	0.000964	0.00353	CbGpPWpGaD
Albendazole—CYP1A1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000933	0.00341	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00093	0.0034	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000803	0.00294	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000793	0.0029	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000765	0.0028	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TMPO—dilated cardiomyopathy	0.000709	0.00259	CbGpPWpGaD
Albendazole—ABCB1—heart—dilated cardiomyopathy	0.000706	0.0205	CbGeAlD
Albendazole—TUBA1A—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000694	0.00254	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000651	0.00238	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000644	0.00236	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000619	0.00227	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000607	0.00222	CbGpPWpGaD
Albendazole—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000595	0.00218	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—LMNA—dilated cardiomyopathy	0.000582	0.00213	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000577	0.00211	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000543	0.00199	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.00054	0.00198	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000502	0.00184	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000485	0.00178	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000484	0.00177	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000483	0.00177	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000473	0.00173	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—AGT—dilated cardiomyopathy	0.00044	0.00161	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000435	0.00159	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.000426	0.00156	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000419	0.00153	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000416	0.00152	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000416	0.00152	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000396	0.00145	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000396	0.00145	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000387	0.00142	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000368	0.00135	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000346	0.00127	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.000326	0.00119	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000312	0.00114	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000304	0.00111	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000304	0.00111	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000294	0.00107	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000282	0.00103	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000265	0.000972	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000265	0.000971	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000265	0.000971	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000257	0.000941	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000253	0.000925	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000253	0.000925	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000248	0.000906	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	0.000242	0.000885	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000239	0.000874	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000234	0.000857	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	0.000219	0.0008	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000205	0.000752	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000205	0.000752	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000203	0.000742	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000193	0.000707	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000175	0.000639	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000164	0.0006	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000155	0.000568	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000154	0.000564	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.000139	0.00051	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000133	0.000488	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.00013	0.000475	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000126	0.000463	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000119	0.000435	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000117	0.000428	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000108	0.000394	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000106	0.00039	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000101	0.000371	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	8.5e-05	0.000311	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.28e-05	0.000303	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	7.45e-05	0.000273	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.16e-05	0.000226	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	5.94e-05	0.000217	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	5.78e-05	0.000212	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	5.21e-05	0.000191	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	4.74e-05	0.000174	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CD36—dilated cardiomyopathy	4.62e-05	0.000169	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AGT—dilated cardiomyopathy	4.16e-05	0.000152	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	3.79e-05	0.000139	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.69e-05	0.000135	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.32e-05	0.000122	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.92e-05	0.000107	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.85e-05	0.000104	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.56e-05	9.38e-05	CbGpPWpGaD
